Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.71 |
| ▸ | MAPT | P10636 | 4/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.55 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30292656 | 1.00 | LMNA (0.71) | LMNAMAPTL3MBTL1ALDH1A1KDM4E | |
| SCHEMBL6969031 | 0.86 | HCRTR1 (0.66) | LMNAMAPTL3MBTL1ALDH1A1KDM4E | |
| SCHEMBL11763044 | 0.86 | HCRTR1 (0.66) | LMNAMAPTL3MBTL1ALDH1A1KDM4E | |
| SCHEMBL206583 | 0.86 | HCRTR1 (0.66) | LMNAMAPTL3MBTL1ALDH1A1KDM4E | |
| SCHEMBL3135517 | 0.85 | LMNA (0.74) | LMNAMAPTL3MBTL1ALDH1A1KDM4E | |
| Benzene SCHEMBL27314454 | 0.84 | ALDH1A1 (0.65) | LMNAMAPTL3MBTL1ALDH1A1KDM4E | |
| SCHEMBL16656684 | 0.84 | LMNA (0.68) | LMNAMAPTL3MBTL1ALDH1A1KDM4E | |
| SCHEMBL124831 | 0.84 | ALDH1A1 (0.65) | LMNAMAPTL3MBTL1ALDH1A1KDM4E | |
| SCHEMBL2117236 | 0.83 | HCRTR1 (0.58) | LMNAMAPTL3MBTL1ALDH1A1KDM4E | |
| SCHEMBL385606 | 0.83 | LMNA (0.72) | LMNAMAPTL3MBTL1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108497-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICALC., LTD. (JP) | 2026-04-23 | — | — | US | disclosed |
| US-20240148699-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-05-09 | — | — | US | disclosed |
| WO-2023127800-A1 | EPOXY RESIN COMPOSITION, CURED PRODUCT, SEALING MATERIAL, AND ADHESIVE | 旭化成株式会社 | 2023-07-06 | — | — | WO | disclosed |
| US-20230212132-A1 | AMINIMIDE COMPOUND, AMINIMIDE COMPOSITION, CURING AGENT, EPOXY RESIN COMPOSITION, METHOD FOR PRODUCING AMINIMIDE COMPOUND, ENCAPSULANT, AND ADHESIVE | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2023-07-06 | — | — | US | disclosed |
| US-11661400-B2 | NADPH oxidase inhibitors, pharmaceutical composition comprising the same, and application thereof | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2023-05-30 | — | — | US | disclosed |
| US-11661400-B2 | NADPH oxidase inhibitors, pharmaceutical composition comprising the same, and application thereof | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2023-05-30 | — | — | US | disclosed |
| US-11661400-B2 | NADPH oxidase inhibitors, pharmaceutical composition comprising the same, and application thereof | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2023-05-30 | — | — | US | disclosed |
| US-20230094105-A1 | ORGANOMETALLIC GELS | UNIVERSITY OF YORK (GB) | 2023-03-30 | — | — | US | disclosed |
| EP-4139039-A1 | ORGANOMETALLIC GELS | University of York (GB) | 2023-03-01 | — | — | EP | disclosed |
| US-11535647-B2 | Peptide purification method using sulfonate compound | NAGASE & CO., LTD. (JP) | 2022-12-27 | — | — | US | disclosed |
| US-4451481-A | ANTICHOLESTEROL AGENTS | SANKYO COMPANY LIMITED (JP) | 1984-05-29 | — | — | US | disclosed |
| US-4447626-A | TREATMENT OF HYPERCHOLESTEROLEMIA | SANKYO COMPANY LIMITED (JP) | 1984-05-08 | — | — | US | disclosed |
| US-4438277-A | Hydronaphthalene derivatives | SANKYO COMPANY, LIMITED (JP) | 1984-03-20 | — | — | US | disclosed |
| EP-0076601-A1 | Octahydronaphthalene derivatives and their preparation | SANKYO COMPANY LIMITED (JP) | 1983-04-13 | — | — | EP | disclosed |
| EP-0074222-A1 | MB-530B derivatives, their preparation and pharmaceutical compositions containing them | SANKYO COMPANY LIMITED (JP) | 1983-03-16 | — | — | EP | disclosed |
| EP-0070649-A2 | ML-236B Derivatives, a process for their preparation and pharmaceutical compositions containing them | SANKYO COMPANY LIMITED (JP) | 1983-01-26 | — | — | EP | disclosed |
| EP-0065835-A1 | M-4 and iso M-4 derivatives, their preparation and compositions containing them | SANKYO COMPANY LIMITED (JP) | 1982-12-01 | — | — | EP | disclosed |
| EP-0065843-A1 | New M-4 and iso M-4 derivatives, their preparation and compositions containing them | SANKYO COMPANY LIMITED (JP) | 1982-12-01 | — | — | EP | disclosed |
| US-4361515-A | Antihyperlipemic dihydro-ML-236B derivatives, their preparation and use | SANKYO COMPANY, LIMITED (JP) | 1982-11-30 | — | — | US | disclosed |
| US-3971825-A | (5,6) (10,11) BIS-METHYLENE, BRONCHODILATORS | SANKYO COMPANY LIMITED (JA) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148699-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | LMNA 3948/4885MAPT 4667/4885L3MBTL1 4602/4885 |
| US-20260108497-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE7B, PDE4B, PDE1B | LMNA 3066/4885MAPT 4216/4885L3MBTL1 4619/4885 |
| US-11661400-B2 | NADPH oxidase inhibitors, pharmaceutical composition comprising the same, and application thereof | NOX1, CYBB, NOX4 | LMNA 4614/4885MAPT 1832/4885L3MBTL1 4867/4885 |
| US-20230212132-A1 | AMINIMIDE COMPOUND, AMINIMIDE COMPOSITION, CURING AGENT, EPOXY RESIN COMPOSITION, METHOD FOR PRODUCING AMINIMIDE COMPOUND, ENCAPSULANT, AND ADHESIVE | ITGAL, VCL, RPL39 | LMNA 1690/4885MAPT 2289/4885L3MBTL1 2574/4885 |
| US-11535647-B2 | Peptide purification method using sulfonate compound | VIP, IAPP, RPS27A | LMNA 4259/4885MAPT 2693/4885L3MBTL1 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.